Monthly Archives: June 2021

"Psoriatic arthritis is a debilitating disease that can cause severe pain, restricted mobility, and lasting structural damage.4, 5The immune system creates inflammation that can lead to skin lesions associated with psoriasis, as well as pain, fatigue and stiffness in the joints," 6,7said Dr. Proton Rahman, FRCPC, Clinical Rheumatologist at Eastern Health and University Research Professor at Memorial University. "Despite treatment advances, somepeople living with PsA do not achieve their treatment goals, which is why access to new therapies is so critical. The approval of RINVOQ offers Canadian physicians and their patients an important new therapeutic option."

"I have had psoriatic arthritis and psoriasis for more than 30 years. At one point, most ofmy body was covered in psoriasis, and I was using arm and leg braces to help me walk. These diseases have had a huge impact on my life, which is why I am so pleased that Canadians with psoriatic arthritis now have a new treatment option available to them," said Marilyn Porth, of Winnipeg, Manitoba.

This approval is supported by data from two Phase 3 studies across a broad range of more than 2,000 patients with active psoriatic arthritis.1,2 In both studies, RINVOQ met the primary endpoint of ACR20 response at week 12 versus placebo.1,2 RINVOQ 15 mg also achieved non-inferiority versus adalimumab in terms of ACR20 response at week 12.1 Patients receiving RINVOQ also experienced greater improvements in physical function (HAQ-DI*) and skin symptoms (PASI 75*), and a greater proportion achieved minimal disease activity.1,2Overall, the safety profile of RINVOQ in psoriatic arthritis was consistent with previously reported results across the Phase 3 rheumatoid arthritis clinical trial program, with no new significant safety risks detected.1,2,8

"The approval of RINVOQ is wonderful news for Canadians living with psoriatic arthritis, and an important step forward for the psoriatic arthritis community," says Wendy Gerhart, Executive Director, Canadian Spondylitis Association. "From our recent member surveys, we know this devastating disease has a profound impact on people's quality of life including their physical and mental health. This approval provides a new treatment option to Canadian patients. It is a hopeful time for people living with psoriatic arthritis."

"For more than 20 years, AbbVie has been dedicated to discovering and delivering innovative therapies for people living with rheumatic diseases," added Tracey Ramsay, Vice President and General Manager, AbbVie Canada. "We are proud of our deep heritage in rheumatology and pleased to expand our portfolio of treatment options for Canadians living with psoriatic arthritis, particularly by offering people the convenience of a once-daily oral medication."

*Physical function was measured by the Health Assessment Questionnaire Disability Index (HAQ-DI). Skin symptoms were measured by a 75 percent improvement in the Psoriasis Area and Severity Index (PASI 75). Minimal disease activity is defined as the fulfillment of five of seven outcome measures: Tender joint count 1; swollen joint count 1; PASI 1 or body surface area-psoriasis 3 percent; Patient's Assessment of Pain Numerical Rating Scale (NRS) 1.5; Patient Global Assessment-Disease Activity NRS 2.0; HAQ-DI score 0.5; and Leeds Enthesitis Index 1.

About SELECT-PsA 1 1,3

SELECT-PsA 1is a Phase 3, multicenter, randomized, double-blind, parallel-group, active and placebo-controlled study designed to evaluate the safety and efficacy of upadacitinib compared to placebo and adalimumab in adult patients with active psoriatic arthritis who have a history of inadequate response to at least one non-biologic DMARD.

Top-line results from SELECT-PsA 1 were previously announced in February 2020. More information on this trial can be found atwww.clinicaltrials.gov(NCT03104400).

About SELECT-PsA 2 2,3

SELECT-PsA 2is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study designed to evaluate the safety and efficacy of RINVOQ in adult patients with active psoriatic arthritis who have a history of inadequate response to at least one biologic DMARD.

Top-line results from SELECT-PsA 2 were previously announced in October 2019. More information on this trial can be found atwww.clinicaltrials.gov(NCT03104374).

About RINVOQ(upadacitinib)

RINVOQ is a 15 mg, once-daily oral medication in an extended-release tablet. It is a Janus kinase (JAK) inhibitor that interferes with the JAK-STAT signaling pathway, which is thought to play a role in inflammatory response.

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate, as well as for adults with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other DMARDs. In RA, RINVOQ may be used as a monotherapy or in combination with methotrexate or other nonbiologic DMARDs. In PsA, RINVOQ may be used as a monotherapy or in combination with methotrexate.

For important safety information, please consult the RINVOQ Product Monograph at http://www.abbvie.ca.

About AbbVie in Rheumatology

For more than 20 years, AbbVie has been dedicated to improving care for people living with rheumatic diseases. Our longstanding commitment to discovering and delivering innovative therapies is underscored by our pursuit of cutting-edge science that improves our understanding of promising new pathways and targets in order to help more people living with rheumatic diseases reach their treatment goals.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at http://www.abbvie.ca. Follow @abbviecanadaon Twitter or find us on Facebook, Instagram, YouTubeand LinkedIn.

References

1.

McInnes I, et al. Efficacy and Safety of Upadacitinib Versus Placebo and Adalimumab in Patients With Active Psoriatic Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Anti-Rheumatic Drugs (SELECT-PsA-1): a Double-Blind, Randomized Controlled Phase 3 Trial. 2020 EULAR E-Congress; LB0001.

2.

Genovese MC, et al. Efficacy and Safety of Upadacitinib in Patients With Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs (SELECT-PsA-2): a Double-Blind, Randomized Controlled Phase 3 Trial. 2020 EULAR E-Congress; OP0223.

3.

RINVOQ (upadacitinib) product monograph. AbbVie Corporation. Available at: https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/RINVOQ_PM.pdf. Accessed June 7, 2021.

4.

Diseases & Conditions: Psoriatic Arthritis. 2019. American College of Rheumatology. Available at: https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Psoriatic-Arthritis. Accessed on: May 13, 2021.

5.

Schett G, et al. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res & Ther.2011; 13(Suppl1) :s4(1-9)

6.

uarte GV, et al. Psoriatic arthritis. Best Pract Res Clin Rheumatol. 2012 Feb;26(1):147-56. doi: 10.1016/j.berh.2012.01.003.

7.

Diseases & Conditions: Psoriatic Arthritis. 2019. American College of Rheumatology. Available at: https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Psoriatic-Arthritis. Accessed: December 2020

8.

Cohen S., et al. Safety profile of upadacitinib in Rheumatoid Arthritis: Integrated analysis from the SELECT Phase 3 Clinical Program. EULAR 2019; THU0167.

SOURCE AbbVie Canada

For further information: Media Inquiries: Julie Lepsetz, AbbVie Canada, (514) 451-9427, [emailprotected]

Continue reading here:
Health Canada Approves AbbVie's RINVOQ (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis - Canada NewsWire

The healthcare vertical is being driven at the consumers pace like never before. In other words, the requirements and goals on their part are driving innovation in every arm of the healthcare vertical. On-demand interactions between clinicians and patients all over the world are being asked for. As such, the healthcare vertical is bound to witness higher strides in the next 10 years.

The Systemic Psoriasis Therapeutics Market is all set to incorporate the ongoing as well as future trend.Psoriasis is an autoimmune skin disease that causes scaling, skin redness and irritation. Psoriasis causes red, scaly patches that are generally found on the elbows, fingernails, scalp, palms, knees, face, feet and inside the mouth. Factors that can trigger psoriasis include infections, heavy alcohol consumption, cold weather, certain medications, smoking, stress and injury to the skin such as bug bite, cut and sever sunburn. The signs and symptoms of psoriasis vary from person to person which includes dry, cracked skin that may bleed, red patches of skin covered with silvery scales, small scaling spots, itching, burning, swollen and stiff joints.

Psoriasis may be classified into various types such as plaque psoriasis, scalp psoriasis, pustular psoriasis, psoriatic arthritis, guttate psoriasis, nail psoriasis, erythrodermic psoriasis and inverse psoriasis. Various treatments for psoriasis are oral medication, topical medication and biologics injections. Psoriasis can also be treating by phototherapy treatment which includes ultraviolet light therapy, laser treatment, tanning beds, psoralen +UVA and sunlight treatment. Psoriasis can occur in any part of the body and it is associated with other health conditions such as heart disease, diabetes and depression.

Get Sample Copy of this Report@https://www.persistencemarketresearch.com/samples/3086

North America, followed by Europe, has the largest market for systemic psoriasis therapeutics due to emergence of novel therapies and rise in treatment seeking population in the region. Asia is expected to show high growth rate in the systemic psoriasis therapeutics market in next few years due to increase in the awareness of disease in the region.

Technological advancement, rise in number of psoriasis patients, development of novel drugs, increasing disease awareness and improvement in diagnostic methods are some of the key factors driving the growth for global systemic psoriasis therapeutics market. In addition, long-term treatment involving continuous uptake of biologics are expected to drive the market for systemic psoriasis therapeutics. However, adverse side effects associated with psoriatic drugs and economic downturns are some of the key factors restraining the growth for global systemic psoriasis therapeutics market.

Request for Table of Content@https://www.persistencemarketresearch.com/toc/3086

Growing demographics and economies in the developing countries such as India and China are expected to offer high growth in systemic psoriasis therapeutics market in Asia. In addition, growing demand of novel therapies for psoriasis treatment is expected to develop good opportunity for global systemic psoriasis therapeutics market. However, safety concern associated with systemic psoriasis therapeutics is expected to lead a challenge for systemic psoriasis therapeutics market.

Some of the major trends that have been observed for systemic psoriasis therapeutics market are increasing use of combination therapies for treating psoriasis, emergence of non-invasive psoriasis treatment and technological advancement in the field.

Some of the major companies operating in the global systemic psoriasis therapeutics market are AbbVie Inc., Stiefel Laboratories, Inc., Biogen Idec, Novartis AG, CELGENE CORPORATION, Takeda Pharmaceutical Company Limited, Pfizer Inc., Amgen Inc., Janssen Biotech, Inc. and Eli Lilly and Company.

Access Full Report@https://www.persistencemarketresearch.com/checkout/3086

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers experience by acting as the missing link between customer relationships and business outcomes. The best possible returns are assured therein.

Contact Us:

Persistence Market ResearchAddress 305 Broadway, 7th Floor, New York City, NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Salessales@persistencemarketresearch.comWebsite https://www.persistencemarketresearch.com

Continued here:
The Systemic Psoriasis Therapeutics Market To Grow On An Unparalleled Note In The Next 10 Years The Courier - The Courier

Psoriasis is a chronic inflammatory skin disorder that is accompanied with various clinical manifestations and is caused due to the involvement of genetic, environmental, and immunological factors

Global Psoriasis Market report studies the overall industry scenario breaking them down in different segments that includes geographic coverage, product type and its application. This report covers the basic market dynamics, market size and companies competition data. In addition, the report also conducts recent market developments, growth analysis by its size or volume, investment return, revenue (value), and consumption (volume) of the global Psoriasis market, ongoing pattern, the effect of covid19 on worldwide or local Psoriasis Market.

This report also covers the impact of COVID-19 on the global market. To Know How COVID-19 Pandemic Will Impact Psoriasis Market |

Get a Sample Copy of Report, Click Here: https://www.reportsweb.com/inquiry&RW00014273008/sample

Key Questions:

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Psoriasis drugs

How many Psoriasis drugs are developed by each company

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Psoriasis

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Psoriasis therapeutics

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies

What are the clinical studies going on for Psoriasis and their status

What are the key designations that have been granted to the emerging drugs

Scope of the Report:

Detailed overview of Psoriasis market Trends

Defining the opportunities and constraints witnessed by the key drivers of the industry

Includes value chain analysis, porter five forces model analysis, CAGR and cost structure analysis

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Company profiling with detailed strategies, financials growth, and recent developments

Get this report at a discounted rate @ https://www.reportsweb.com/inquiry&RW00014273008/discount

This report offers detailed TOC of Psoriasis Market:

Psoriasis Product Definition

Global Psoriasis Market Manufacturer Share and Market Overview

Manufacturer Psoriasis Business Introduction

Global Psoriasis Market Segmentation by (Region Level, Product Type Level, Industry Level, Channel Level

Psoriasis Market Forecast

Psoriasis Segmentation Product Type

Psoriasis Segmentation Industry

Psoriasis Cost of Production Analysis by (Raw Material Cost Analysis, Technology Cost Analysis, Labor Cost Analysis, Cost Overview, Conclusion

To get this report at a profitable rate @ https://www.reportsweb.com/buy&RW00014273008/buy/3000?source=shikha

Contact Info:Name: Sameer JoshiEmail:sales@reportsweb.comCompany Name: ReportsWebWebsite: Reportsweb.com

Phone: +1-646-491-9876

About ReportsWeb:

ReportsWeb.com is a one stop shop of Market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Read the rest here:
Psoriasis Market Emerging Competitive Strategies, Key Manufacturers, New Project Investment by 2025 The Manomet Current - The Manomet Current

This article is a sponsored collaboration between Bodewell and PAPER

For people living with skin conditions like eczema and psoriasis (and compromised skin), the journey to self-improvement and acceptance can be a long and arduous process. In the US alone, eight million people have been diagnosed with psoriasis, while over 30 million have eczema.

But even though these skin conditions (there is still no known cure) are relatively common, the psychological effects take a considerable toll on mental health. According to a National Eczema Association study, participants were three times at a higher risk for depression or anxiety, while 50% said their conditions interfere with their social life and intimate relationships.

When it comes to skincare brands that are focused on helping people who suffer from these skin conditions, they are underwhelming both from a product perspective, and a human empathy perspective.

Bodewell, a medicated skincare company tailored to people with eczema, psoriasis and sensitive skin, has set out to change this status quo. Its ultimate mission is to de-stigmatize skin conditions and build a supportive community around those on their healing journey, which is often inextricably linked to self-love and self-worth.

The brand's co-founder, Jamie Duff, suffered from severe eczema for 30 years and launched Bodewell as an answer to the struggles he faced. Over the years he explored holistic treatments such as vedic meditation, yoga, yogic breathing and cognitive behavior therapy that all take a more human-centered approach to the inner and outer effects of the origins of these inflammatory skin conditions. He thinks this approach can also benefit others.

More directly, Bodewell has developed (alongside CPG powerhouse P&G) treatments that they refer to as "next generation medicated skincare": plant-technology powered, scientifically-tested and proven, unique anti-inflammatory mechanism of action that hydrates, stops itching, repairs skin barrier and prevents future flare-ups. There's also a personalized digital and mobile program that supplements the products and supports customers through their journey. This program draws on co-founder Jamie's own experiences.

To capture the overlooked beauty of chronic skin sufferers, Bodewell launched an ongoing portrait series named Skincare For the Rest of Us, where it highlights real sufferers on their own terms. In this special editorial feature shot by Issey Gladston (an eczema sufferer herself) the portraits celebrate the scars as a visual tale of strength, perseverance, overcoming adversity and embracing self-love.

What's something people who have never experienced your skin condition be surprised to know or don't know about what it's like to live with it?

Human beings are preconditioned to prefer that which is aesthetically pleasing, so naturally a skin condition attracts attention because it looks different. I think a lot of people are surprised when they realize it can be quite sore/painful and can even impact common everyday tasks like sleep. My own personal experience has reminded me that skin is not an aesthetic. Skin is for function touch, temperature regulation, process pain. Our largest organ keeps all our other organs safe.

How were you able to come to terms with your condition and overcome any obstacles you've had to endure?

Self acceptance. Accepting how you have been created and navigating it to the best of your ability is the first step to overcoming. There is a silver lining in everything. My skin condition realigned me to my true creative purpose modeling and painting.

How has Bodewell helped you on your journey to self-improvement and acceptance?

I have been campaigning for brands to shoot atopic skin since 2017. It was important for me that brands particularly dry skin and atopic skin brands who include their target market in their modeling campaigns understand our lived experiences and not sell unrealistic dreams of perfect skin to those living with chronic skin conditions. Bodewell has championed skin representation and created opportunities for me as a skin model. My confidence goes up every time I shoot with Bodewell and I feel motivated to challenge other brands to shoot and include atopic skin.

What's something people who have never experienced your skin condition would be surprised to know or don't know about what it's like to live with it?

I think a lot of people would be surprised to know psoriasis is not contagious in any way. Living with my plaque psoriasis can be very sore and itchy, but it's taught me a lot of self-confidence.

How were you able to come to terms with your condition and overcome any obstacles you've had to endure?

Instagram helped me a LOT with coming to terms with my skin condition. My skin progressed slowly over many years, but with it my confidence also grew. In regards to obstacles, I've had to get used to my skin getting more sore and flaky over the last couple of years but it's something I am learning to come to terms with.

How has Bodewell helped you on your journey to self-improvement and acceptance?

Bodewell has helped me massively to embrace my skin and also to try new things, such as the photo shoot, that would normally be so outside of my comfort zone. They're an amazing company that genuinely care and really help me and the other girls to embrace our skin.

What's something people who have never experienced your skin condition would be surprised to know or don't know about what it's like to live with it?

The fact that my skin reproduces at the speed it does! I can go to sleep with a clear face and wake up a few hours later to new patches out of nowhere! You never know what you will get with psoriasis. Another classic favorite of mine is having a brush and dustpan on standby for the morning when it's time to get all my fallen skin from scratching all night off the bed and off the floor.

How were you able to come to terms with your condition and overcome any obstacles you've had to endure?

I got to a point where hiding it was no longer an option it was draining physically and mentally. I put 100% into hiding something about myself simply because I didn't want to make other people uncomfortable, but I finally got to a point where I needed my comfort to be more important than those of other people. I needed to put myself first for once.

How has Bodewell helped you on your journey to self-improvement and acceptance?

Bodewell helped me to let go of the fear of not being on medication. I felt dependent on prescription medication. If I didn't have it, that would mean a flare up and there was no way I could allow that. I only ever truly accepted the Michelle who would occasionally have clear skin from time to time but flare-up Michelle was difficult to love. Bodewell opened my eyes to different ways of healing my skin. I no longer feel dependent on medication and I'm happy with myself with or without a flare. I now understand that I'm on a journey with my condition and it's not one I need to rush.

What's something people who have never experienced your skin condition would be surprised to know or don't know about what it's like to live with it?

It is surprisingly beautiful, the way in which it inhabits certain areas of the skin, in the most fascinating accumulation of patterns is quite amazing.

How were you able to come to terms with your condition and overcome any obstacles you've had to endure?

Self-acceptance and patience. It can be quite a debilitating condition to deal with. However, learning the skill of self-acceptance and love for oneself helps to overcome those debilitating obstacles.

How has Bodewell helped you on your journey to self-improvement and acceptance?

Bodewell offered me a community where I felt safe to discuss my skin condition and tips on living with a skin condition. They gave me modeling opportunities which helped with my self-confidence and to become an active skin campaigner.

What's something people who have never experienced your skin condition be surprised to know or don't know about what it's like to live with it?

Surprisingly, my confidence in my body image, character and relationships with others has really been amplified whilst going through my journey with psoriasis. We usually hear stories relating to the negatives to having a skin condition which is just as important, however, my perspective on other aspects of my life has really changed for the better!

How were you able to come to terms with your condition and overcome any obstacles you've had to endure?

Growing up since the age of 9 with psoriasis being an extremely sporty young girl, I've almost been forced into dealing with my skin, but it wasn't until lockdown 2020 (the time of my worst flare up) that I was literally left to do nothing but look at myself daily and learn to accept, love and nurture my skin with every itch of itself.

How has Bodewell helped you on your journey to self-improvement and acceptance?

Seeing the large community that was built by so many inspiring people be celebrated by a brand like Bodewell, particularly having all-women shoots, is extremely refreshing and comforting. The creams and serums have become staples in my regime and I've definitely stepped up my skincare game to the next level. Their products are not only amazing for me, but they truly reach such a wide audience which I know will continue to grow into a wholesome and well-loved brand.

What's something people who have never experienced your skin condition would be surprised to know or don't know about what it's like to live with it?

I think the one thing I'd like people to know who have never had to deal with eczema is that it is not just a dry skin condition. It's so much more than that. It's debilitating and, depending on the severity, life altering. We have to cater our whole lives around our skin. It's not something as simple as making sure you've put moisturizer on for the day. It's the constant itching that never ends and feels like you can never do enough. It's the painful tears and cracks as our skin is so sensitive that just a touch will have it crumble. It's always worrying about skin infections due to this. It's being terrified to have a shower because the water feels like knives on our skin. It's always having to worry about the weather conditions and if we've prepped our skin well enough including having to make sure we have all our cream and medicines in our bag if we know we'll be out of the house for longer than 5 minutes. I could go on and on but I need people to know that just applying e45 isn't the solution to our problem.

How were you able to come to terms with your condition and overcome any obstacles you've had to endure?

I was always tired of not seeing the representation we as a community deserve and pushing for more inclusivity, especially as a dark skinned South Asian woman, is something that I am very passionate about and always pushing for in all sectors. So my support system, who come in the form of my best friends and the online eczema and TSW community, really gave me the confidence to put myself out there especially on social media where your appearance is held to such a high unrealistic standard and has made me realize that beauty will forever and always be more than skin deep and made me see real beauty that isn't just on the outside.

How has Bodewell helped you on your journey to self-improvement and acceptance?

I am so grateful for platforms like Bodewell, who not only provide products for people which chronic skin conditions, but also allow us to have a voice and spread awareness. Being able to not only have your say, but also listen and hear others who you can relate to has massively helped. Knowing that even though we still have a long way to go with gaining social acceptance and inclusivity, they are helping pave the way for so many of us warriors and are helping make a happy healthy change in the way we see beauty and skin conditions.

Photography: Issey Gladston

Related Articles Around the Web

See more here:
Bodewell Is the Community-Powered Brand for Chronic Skin - PAPER - Papermag